Beckwith-Wiedemann syndrome is a typical example of this association [Shuman et al., 2000] .
Asymmetric overgrowth or hemihyperplasia occurs in patients with Beckwith-Wiedemann syndrome (MIM 130650), but can be an isolated finding. An increased risk for malignant tumors, particularly for Wilms tumor, has been documented in individuals with Beckwith- Wiedemann syndrome or isolated hemihyperplasia (MIM 235000). Hemihyperplasia is genetically heterogeneous, including genomic abnormalities seen in Beckwith-Wiedemann syndrome, as well as mosaic chromosome or genomic abnormalities and somatic point mutations. Somatic mutations affecting the PI3K-AKT-MTOR pathway result in segmental overgrowth and other physical findings. Similarly, somatic mutations affecting the PI3K-AKT pathway are present in numerous benign and malignant tumors (see [Samuels and Waldman, 2010] for review). In individuals presenting in early childhood with segmental overgrowth or other findings related to somatic mutations in the PI3K-AKT-MTOR pathway, the mutation inherently occurred during an early developmental stage and may result in an increased lifetime risk for neoplasias driven by mutations in this pathway. Detailed understanding of the clinical phenotypes related to these mutations [Lee et al., 2012; Lindhurst et al., 2012; Poduri et al., 2012; Rios et al., 2012; Riviere et al., 2012; Kurek et al., 2012; Mirzaa et al., 2013; KepplerNoreuil et al., 2014; Keppler-Noreuil et al., 2015] may allow for delineation of the associated cancer risks based on the specific mutation and the affected cell lineages. Here we report two individuals with somatic mosaicism for the most common PIK3CA mutations, c.3140A>G 
MATERIALS AND METHODS
Patient 1 was evaluated clinically and testing for overgrowth was completed clinically. Informed signed consent was obtained, and clinical data, clinical photographs and molecular results were reviewed. Patient 2 was enrolled in a somatic overgrowth study and evaluated at the National Institutes of Health after obtaining informed consent. She was previously reported as patient 23
in Keppler-Noreuil et al. [2014] . Updated history, exam and testing were obtained for this report.
We reviewed the literature and reviewed cohort data in order to gather information on the frequency of Wilms tumor and nephroblastomatosis in individuals with somatic PIK3CA mutations.
Cambridge cohort
This study was approved by the UK National Research Ethics Committee. Written informed consent was obtained from all participants or their parents. Genomic DNA was extracted from lesions using standard procedures and imaging was conducted as part of routine clinical care.
Somatic PIK3CA mutations were detected in affected tissues using Next Generation Sequencing with preceding target enrichment. Equipment and materials were purchased from Life
Technologies, Thermo-Fisher Scientific using a custom-designed primer pool which provides coverage of all coding regions of PIK3CA and related genes (primer sequences available on F o r P e e r R e v i e w request). The mean depth of coverage for sequencing was 2000X. Mutations were verified to be disease-causing on the basis of; i) finding the same mutation in additional probands with a similar phenotype ii) published experimental data confirming activation of downstream effectors of PI3K, and/or iii) the presence of the mutation in the catalogue of somatic mutations in cancer (COSMIC) [Forbes et al., 2015] .
Clinical Reports

Patient 1
The proband was born vaginally at 35 weeks of gestation after a pregnancy complicated by maternal urinary tract infection and possible polyhydramnios on prenatal ultrasound. His G2P1->2 mother was 22 years old and his father was 26 years old. His African American parents were non consanguineous. One maternal and three paternal half-sibs were in good health. Birth weight was 2.47 kg (25-50 th centile for gestational age) and length 48.3 cm 75 th centile for gestational age). OFC was not documented. Asymmetric overgrowth with right thigh enlargement was present from birth and resulted in evaluations for hemihyperplasia. At age 5 months, physical examination was remarkable for bilateral supranumerary nipples, increased girth in the right leg compared to the left, and a hypopigmented lesion on the lower abdomen.
A small left kidney with enlargement of the right kidney was noted on ultrasound at age 5 weeks. Renal ultrasound at age 9 months showed three well defined hypoechoic avascular masses in the right kidney measuring 1.3x1.1x1.4 cm, 1.6x1.4x1.4 cm and 1.7x1.3x1.4 cm, respectively ( Figure 1a ). The lesions were confirmed by CT study (Figure 1b, c) , which incidentally showed a marked asymmetry of the paravertebral and pelvic musculature with all 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 1d ). Wilms tumor was diagnosed and chemotherapy administered in an effort to allow surgery later with preservation of kidney function. This decision was in consideration of his atrophic left kidney, which contributed 23% to total renal function. A subsequent CT scan (Fig. 1c) demonstrated the tumors' sizes to be unchanged or increased, and a needle biopsy was performed at age 10 months. In this post-treatment biopsy the pathology diagnosis was a nephrogenic lesion, it was impossible to differentiate between nephrogenic rests and Wilms tumor. Chemotherapy was completed as planned. The lesions responded to therapy and were monitored through imaging studies. Surgical resection was not performed.
A soft lipomatous mass in the right paraspinal region above the iliac crest was first documented at age 2 years. An MRI at age 7 years showed a 2.8x2.8x10 cm focus of abnormal signal intensity within the right vastus lateralis muscle. An MRI at age 7 10/12 years showed the same stable lesion and regions of post contrast enhancement in the right iliac muscle (Figure 2 , a-d). Fatty lobules in the left paraspinal soft tissue at L3-L5 appeared stable compared to previous studies and did not encroach on the neural foramina. The right L3 root was anteriorly displaced, implying fatty infiltration in the right L3-L4 neural foramen. Stable fatty prominence in the right L5-S1 neural foramen was noted. Due to discomfort, the paraspinal intramuscular lipoma was surgically removed at age 8 years. Pathology showed mature adipose tissue encompassing skeletal muscle, consistent with an intramuscular lipoma.
The size discrepancy of his legs persisted. An enhancing lesion in the right psoas was seen on MRI ( Figure 2b ) and a needle biopsy results obtained at age 4 years suggested an inflammatory myopathy. The entire right leg was larger than the left in diameter and the right (Figure 3a) , and the leg size discrepancy was striking (Figure 3b , c).
Molecular Laboratory Study Results
An overgrowth panel was performed clinically on a next generation platform at the show the mutation with a confidence score of 99.99%, leading to the conclusion that the mutation occurred somatically. 
Patient 2
This individual was originally reported as patient 23 in Keppler-Noreuil et al. [2014] and clinical information was updated at age 10 years. The proposita was born at 38 weeks' gestation by induced vaginal delivery after a pregnancy complicated by abnormal prenatal ultrasounds revealing "webbed toes" on her right foot and "white spots" on her heart. Her G1P0-1 mother was 21 years and her father was 26 years old. Her African American parents were nonconsanguinous and subsequently had a healthy son. Birth weight was 2.95 kg (10-25 th centile) and length 49.5 kg (50 th centile). Her right leg and foot, including her toes were noted to be enlarged, and she had hyperpigmentation of her neck and waist.
At age 2 years, she was found on renal ultrasound imaging to have bilateral hypodense renal lesions. She was diagnosed with Wilms tumor. She was treated with 4 months of chemotherapy with vincristine, actinomycin, and adriamycin followed by bilateral partial nephrectomies. Pathology from the nephrectomies showed adenomatous nephrogenic rests.
Her renal function has been normal. At age 10 years, abdominal ultrasound showed stable size asymmetry of the kidneys with no change in the moderate hydronephrosis involving the right kidney; parenchymal thinning with increased cortical echogenicity of the right kidney, and normal corticomedullary differentiation of the left kidney with an unchanged nephrogenic rest. She has had progressive overgrowth of her right leg and foot with leg length discrepancy. She has undergone multiple orthopedic surgeries including right foot Boyd amputation at age 2 years and epiphysiodesis of the right femur and hemiepiphysiodesis of the right tibia at age 4 years. An MRI scan of her lower extremities at 6 years showed diffuse multicompartmental lipomatosis of the lower extremities with muscular infiltration, right greater than left with right buttock and leg enlargement and muscle atrophy. Right patellar dislocation was present associated with the intra-articular lipomatosis. Liposuction of her right leg was performed at age 6 years, and debulking of her right knee at 7 years. She had eight-plate removal from the right lateral proximal tibia, medial distal femur and lateral distal femur at 7
years. She underwent laparoscopic surgery to remove excess subcutaneous fat from the right side of her abdomen at age 8 years.
Her motor and speech development were apparently normal. She crawled at 6 months, walked at 10 months, drank from a cup at 11 month, spoke in 2 word sentences at 12 months, toilet trained at 14 months, and was riding a 2 wheel bike at 8 years. She was in a regular class setting with additional help in math. She was diagnosed with attention deficit disorder at age 9 years.
On examination at 10 years, her height was 139. (Figure 4 ,a-d).
Molecular Laboratory Study Results
Molecular analysis consisted of candidate mutation analysis for somatic mutations in PIK3CA using a custom PCR restriction assay as described in Lindhurst et al. [2012] for the c.3140A>T p.His1047Leu mutation. This mutation was found in adipose and skin samples from the left leg at the level of 3-4%, with negative results from peripheral blood.
PTEN mutation analysis was normal.
RESULTS
Literature Review and Cohort Data
Literature review revealed two reports including individuals with a somatic PIK3CA mutation and Wilms tumor [Kurek et al., 2012; Luks et al., 2015] (Table I) . Keppler-Noreuil et al. [2014] reviewed the clinical and natural history of PIK3CA related overgrowth spectrum in a cohort of 35 individuals (Table II) , including one reported here with updated history and findings as Patient 2. Further, two patients with Wilms tumor and megalencephaly-capillary malformation (MCAP) (602501) syndrome were reported prior to the identification of the molecular basis of MCAP [Lapunzina et al., 2004; Wright et al., 2009] . Table II .
DISCUSSION
The two patients described here were diagnosed with renal masses at 9 months and 2 years of age, respectively. Imaging studies in both identified hypodense masses in the kidneys suggestive of Wilms tumor. In the first patient, pathology from needle biopsy performed after treatment was indeterminate regarding the diagnosis of Wilms tumor versus nephrogenic rests.
In the second patient, pathology showed adenomatous nephrogenic rests. Both patients were treated with chemotherapy, and their follow up studies have been stable. Very few patients with hemihyperplasia due to a somatic PIK3CA mutation and Wilms tumor or nephroblastomatosis have been reported (Table I) . Nephrogenic rests or nephroblastomatosis refer to foci of embryonal cells persisting beyond 36 weeks of gestation and capable of developing into nephroblastomas (Wilms tumor) [Murphy et al., 2004] . These are found in 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [Lonergan et al., 1998 ]. Nephroblastomatosis is associated with syndromes including Beckwith-Wiedemann syndrome, isolated hemihyperplasia, chromosomal abnormalities and aniridia [Scott et al., 2006a] (Table I) [Luks et al., 2015] .
Neither the individuals reported here nor the patient in Kurek et al. [2012] had megalencephaly. This is noteworthy because the phenotypic spectrum associated with PIK3CA mutations encompasses MCAP syndrome, a clinically distinct disorder manifesting predominantly with severe brain overgrowth, and milder body overgrowth than other PIK3CA-related disorders [Mirzaa et al., 2013] . In a series of 12 patients with MCAP, one had a Wilms tumor [Wright et al., 2009] . This 4-year-old male patient had lipomas and a dermatomyofibroma. He did not show a PTEN mutation, no other testing was reported [Wright et al., 2009] . Another patient with MCAP and Wilms tumor has been reported [patient 2, Lapunzina et al., 2004] . This 10 month old girl had megalencephaly, hydrocephalus, cutaneous [Lapunzina et al., 2004] . We are not aware whether this patient has been tested for PIK3CA mutations.
Somatic PIK3CA Mutation Associated Phenotypes Phenotypes associated with somatic PIK3CA mutations are extremely variable, depending upon the timing and location of their postzygotic occurrence and the effect of the specific amino acid on the protein product. This phenotypic spectrum is now referred to as PIK3CA-Related Overgrowth Spectrum (PROS) [Mirzaa et al., 2013; Keppler-Noreuil et al., 2014] and encompasses a number of originally clinically defined conditions. The MCAP syndrome was previously known as macrocephaly-cutis marmorata teleanciectasia congenita or macrocephaly-cutis marmorata and is primarily distinguished by brain overgrowth (megalencephaly or hemimegalencephaly) with associated neurologic complications (hydrocephalus, Chiari malformation), cutaneous capillary malformations with focal or generalized somatic overgrowth and syndactyly or polydactyly, as well as variable connective tissue dysplasia [for review see Mirzaa et al., 2013] . The CLOVE syndrome is defined by congenital lipomatous overgrowth, vascular malformations and epidermal nevi [Sapp et al., 2007] and shows significant overlap with fibroadipose hyperplasia. The acronym was extended to CLOVES in order to account for skeletal anomalies, scoliosis, spinal anomalies and seizures [Alomari 2009 ]. The CLOVES syndrome may be differentiated from MCAP by the severity of somatic overgrowth with characteristic overgrowth of lipomatous tissue and high risk of lymphatic and vascular malformations in the former; whereas brain overgrowth predominates in MCAP and somatic manifestations, while present, are typically milder than in CLOVES [Kurek et al., 2012 ]. In the majority of patients with Klippel-Trenaunay syndrome, isolated lymphatic malformation or a combination of findings including fibro-adipose vascular anomalies, mutations in PIK3CA were identified [Luks et al., 2015] . A wide range of unusual presentations has been described in case reports, including unilateral hand muscle overgrowth [Castiglioni et al., 2014] , segmental overgrowth syndrome [Rasmussen et al., 2014] and mesenteric lipomatosis [Cohen et al., 2014] . The most common mutation is a postzygotic change affecting amino acid 1047, with p.His1047Arg in 19 and p.His1047Leu in 8 of 35 individuals reviewed by Keppler-Noreuil et al. [2014] (Table II) . While the CLOVES syndrome or fibroadipose hyperplasia phenotype appears to be common in individuals with a missense mutation at codon 1047, individuals with a clinical diagnosis of Klippel-Trenaunay syndrome or isolated lymphatic malformation [Kurek et al., 2012; Luks et al., 2015] also had a mutation affecting this amino acid. Keppler-Noreuil et al. [2014] differentiated between mutations at p.His1047, which affect the catalytic domain of the protein product, and multiple other changes in the coiled domain The catalytic subunit of phosphatidylinositol-3-kinase (PI3K) is somatically mutated in many cancers including colorectal, ovarian, breast, hepatocellular carcinomas and glioblastomas.
These PIK3CA mutations are located mostly at hotspots within the kinase domain (encoded by exon 20), and result in gain-of-function implicated in oncogenicity [Samuels et al., 2004; Ikenoue et al., 2005; Kang et al., 2005] . However, isolated Wilms tumor has not previously been reported in association with somatic PIK3CA mutations. The risk of tumorigenesis, including Wilms tumor, in patients with isolated hemihyperplasia ranges from 3.3-6% [Hoyme et al., 1998; Lapunzina 2005; Clericuzio and Martin, 2009] . Wilms tumor has been reported in four individuals with phenotypes associated with somatic PIK3CA mutations, including the two described here.
Wilms Tumor Screening Recommendations
Screening has been recommended for young children with syndromic conditions encompassing an increased risk for Wilms tumor, most classically Beckwith-Wiedemann syndrome [Beckwith 1998; Choyke et al., 1999; Clericuzio and Martin, 2009] . Based on the perceived difference in the tumor risk ranging from high in isolated hemihyperplasia to mild or moderate in KlippelTrenaunay and macrocephaly-capillary malformation syndrome[ Lapunzina [Table V in Lapunzina 2005] reviewed the screening guidelines for multiple overgrowth syndromes and as expected, the abdominal ultrasound recommendations were identical for isolated hemihyperplasia and Beckwith-Wiedemann syndrome with screening every 3 months until age 4 years, every 6 months until age 7 years and annually thereafter. In contrast, it was recommended that individuals with MCAP receive an annual abdominal ultrasound in all age groups [Lapunzina, 2005] . The American College of Medical Genetics practice guidelines for Wilms tumor screening in patients with isolated hemihyperplasia suggest abdominal ultrasound every 3 months until age 7 years [Clericuzio and Martin, 2009] [Ehrich et al., 1979] and bilateral nephroblastomatosis [Mankad et al., 1974] in individuals with KlippelTrenaunay syndrome, no recent reports of this association have been published. Importantly, these screening recommendations [Green et al., 2004; Lapunzina 2005] were published before the molecular characterization of Klippel-Trenaunay syndrome, and the clinical diagnosis of Klippel-Trenaunay syndrome is not always consistently defined, making it difficult to determine whether reported individuals actually had PROS or another overlapping disorder. Some patients with hemihyperplasia have an underlying somatic PIK3CA mutation and their increased risk for Wilms tumor, and possibly other embryonal tumors, may be at least partially accounted for by the PIK3CA mutation. Given the prevalence of PIK3CA mutations affecting codon 1047 in cancer, a critical consideration is whether patients with these particular mutations are at Table II and after adding Patient 1 reported here is 258. Considering ascertainment bias for the Patient 1 in this report it is likely that the risk for Wilms tumor or nephroblastomatosis in individuals with PIK3CA mutations is less than the calculated 4/258 or 1.6%. While this risk is increased compared to the general population, it does not meet the 2-5% risk suggested by Scott et al. [2006b] in order to warrant screening studies. However, in light of the clearly increased risk and the variable preferences of families and medical care providers in different care environments, we consider screening by ultrasound appropriate, similar to the recommendations for hemihyperplasia [Clericuzio and Martin, 2009] , as indicated in Table III. Because many individuals with PROS have overgrowth, the screening guidelines for hemihyperplasia [Clericuzio and Martin, 2009 ] would be applied prior to the identification of a PIK3CA mutation.
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